Recent Alzheimer’s drug disappointment illuminates pathway for progress against the disease
By a
The letter expresses gratitude to
In the letter, Vradenburg also stressed that the Solanezumab news underscores the need for more aggressive dosing and testing even earlier in the disease course. Solanezumab targets the beta amyloid protein that forms most of the plaque that builds up in the brains of Alzheimer's patients, and many researchers remain convinced that beta amyloid is a principal hallmark of the disease and a critical target for disease modification. Vradenburg urges the field to assess more aggressive dosing when treating this fatal disease.
"Patients and families experiencing this disease have limited and minimally effective pharmacological options," Vradenburg said. "They are demanding aggressive treatments. The devastating effects of Alzheimer's and our limited therapeutic arsenal mean that, for many with the disease, the possibility of treatment benefits far outweighs the risk of the most common side effects associated with anti-amyloid therapies. We should reflect this perception in our approach to clinical trial dosing, which has been relatively constrained in the past. Moreover, even modest disease-modifying interventions during earlier stages of disease would produce powerful cumulative effects over time that could delay or prevent symptoms of the disease."
Vradenburg emphasized that Solanezumab's results escalate the need to double down on other efforts to end Alzheimer's, incidences of which will triple by 2050. Among those efforts are the following:
"Recent trial results must embolden us, not discourage us," he said. "Moreover, they must move us to collaborate more broadly to increase the speed of learning and the acceleration of innovative medicines to those with or at risk of Alzheimer's."
Click here to view the letter.
Keywords for this news article include: Amyloid, Dementia, Proteins, Tauopathies, Clinical Research, Risk and Prevention, UsAgainstAlzheimer's, Diagnostics and Screening, Clinical Trials and Studies, Brain Diseases and Conditions, Central Nervous System Diseases and Conditions, Neurodegenerative Diseases and Conditions - Alzheimer Disease.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC


Elephant launches new ad campaign with Dallas country music star
EPR Properties Announces Tax Status of 2016 Distributions
Advisor News
- Election results cloud retirement legislation outlook, experts say
- Planning for the missing chapter
- Semi-retirement: helping clients balance flexibility with financial security
- The 6X Formula for leveraging content marketing with AI
- When a home becomes difficult to insure, the plan changes
More Advisor NewsAnnuity News
- Athene CEO criticizes offshore reinsurance, risk-taking by competitors
- DOL, trade groups, state AGs file briefs supporting Alcoa in PRT lawsuit
- John Hancock launches new fixed indexed annuity suite
- Annuities to play a larger role in workplace retirement plans
- FHLBank Pittsburgh Announces Results in 2026 Board Election
More Annuity NewsHealth/Employee Benefits News
- Health insurers leave Ohio marketplace
- Rising hospital, drug costs boost health insurance premiums at fastest pace since start of Obamacare
- Patients with 3 health insurance plans lose access to Miami health network
- Weld County deputy struggling after being injured by DUI driver (photo gallery)
- Changes to Medicare Advantage plan offerings affect Montana seniors
More Health/Employee Benefits NewsLife Insurance News
- Best’s Market Segment Report: AM Best Maintains Stable Outlook on New Zealand’s Non-Life Insurance Segment
- AM Best Affirms Credit Ratings of Fubon Insurance Vietnam Co., Ltd.
- Three lawsuits put life insurers’ cost-of-insurance practices under scrutiny
- Military Briefs: November 12-18
- Security Benefit Series B Preferred Stock Dividend Rate Resets to 10.286%
More Life Insurance News